IL33 and cancer: Extensive evidence from a variety of studies has suggested that the IL-33/ST2 axis promotes esophageal inflammation; therefore, the IL-33/ST2 axis might function as a possible biotherapeutic target for both esophageal inflammatory diseases and cancers.